Hypercholesterolemia Clinical Trial
Official title:
Interventions for Chronic Diseases: Effect of Patient Values and Effectiveness Information on Patients' Choice of Therapy, Adherence to Therapy and Satisfaction With Therapy
Few studies have explored how specific formats of effectiveness information effect on real
patients' decisions. We only know little about what kind of format would be the optimal to
help patients make well-informed real-life decisions corresponding to their preferences.
The trial is developed in a clinical randomised design to study risk communication in the
shared decision making between general practitioners (GP) and their patients in primary
prevention with of cholesterol lowering drug. Endpoints are effect of GPs' information about
treatment effectiveness and their patients' values on patients' tendency to accept and
adhere to the treatment as well as their feeling of content with the choice made. GPs are
randomised to inform about risk and treatment effectiveness by means of either absolute risk
reduction (ARR) or Prolongation of Life (POL). Afterwards patients are invited to answer
questionnaires concerning their content with decisions and reflections. Patients' redemption
of prescriptions during the following week and the first year are recorded through an
electronic database.
57 GPs and 248 patients have been enrolled in the trial.
As chronic diseases are steadily increasing in the industrialized countries, there is a
growing focus on preventive initiatives. This means that risk communication between the
physician and his patients plays a central role.
Effective risk communication can enhance knowledge, involvement in decisions about tests or
treatment, autonomy and empowerment of patients. Poor communication, however, can lead to
anxiety, lack of confidence in health care professionals, and other adverse outcomes. It is
vital that we identify the available evidence about how it should best be done.
The standard formats used to communicate intervention effectiveness are absolute risk
reduction, relative risk reduction, number needed to treat, and life prolongation of life.
Few studies have explored the formats' influence on real patient decisions, implying that we
only know little about what kind of format would be the optimal to help patients make
well-informed real-life decisions corresponding to their preferences.
In a clinical randomized design risk communication is studied in the preventive talk between
the general practitioner (GP) and his patients concerning cardiovascular diseases. Special
focus is on influence of information format on patients' choice of therapy, adherence to
therapy and satisfaction with therapy.
GPs are randomized to one of two groups, being taught in informing their patients by means
of either absolute risk reduction, ARR or life extension, LE.
The setting is the preventive talk in the GP's clinic. From a measured total-cholesterol the
GP informs his patient about the individual risk of getting a cardiovascular disease and the
possible effectiveness of a cholesterol-lowering drug. This is done by means of either ARR
or LE. After the talk the patient is invited to answer a questionnaire concerning personal
experience with the information given (deadline 2 weeks after the talk), and again after 3
months will receive a questionnaire concerning satisfaction with the decision made and
reflections. Patients' redemption of prescriptions during the following week and the first
year are recorded through Odense PharmacoEpidemiological Database, OPED. The GPs' opinions,
experiences and concerns about risk communication, prevention, and usage of statins are
explored by means of questionnaires.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Recruiting |
NCT03947866 -
Ezetimibe-Rosuvastatin Evaluation Study
|
||
Completed |
NCT01709513 -
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
|
Phase 3 | |
Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
Completed |
NCT02550288 -
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
|
Phase 3 | |
Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
Completed |
NCT04485793 -
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
|
N/A | |
Completed |
NCT02341924 -
Validating the "Foods for Health" Portfolio of Functional Food Products
|
N/A | |
Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
Completed |
NCT01934608 -
The Effect of Synching Prescription Refills on Adherence
|
N/A | |
Completed |
NCT01941836 -
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
|
Phase 2 | |
Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
Completed |
NCT01670734 -
Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01678521 -
Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients
|
N/A | |
Completed |
NCT01370590 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
|
Phase 3 | |
Completed |
NCT01370603 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
|
Phase 3 | |
Completed |
NCT01575171 -
Using Nudges to Implement Comparative Effectiveness
|
N/A | |
Completed |
NCT01446679 -
Special Drug Use-Results Survey of Lipitor Tablets
|
N/A | |
Completed |
NCT01768403 -
Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
|
N/A |